Company Overview
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a human connective tissue matrix compromised of amniotic tissue intended for wound covering; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Why Investors Should Care
Return on capital employed stands at 75.7%.
Net profit has compounded at 768.6% per year over the last five years.
Revenue has grown at a 311.2% CAGR over the past five years.
Trades at a P/E of 4.2, below the sector median of 25.2.
Carries low leverage with a debt-to-equity ratio of 0.10.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2024 Revenue of $301.83M (+1708.9% YoY); net profit $31.88M.
- Trailing 12 Months Year-on-year growth — revenue -61.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 311.2%, profit CAGR 768.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 311.21% |
| 1 Year: | -61.60% |
Compounded Profit Growth
| 5 Years: | 768.65% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -65.25% |
| 6 Months: | -28.79% |
| 3 Months: | -4.77% |
| 1 Month: | -7.71% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)52.40 · Neutral
P/E of 4.22 is below the sector median of 25.17 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 75.7%.
- Compounding revenue at 311.2% over 5 years.
- Profit CAGR of 768.6% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 65.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BSEM BioStem Technologies, Inc. PHARMA | 3.71 | 4.22 | $63.01M | 0.00% | 75.72% | -48.64% | 311.21% | 768.65% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Sep 2025 |
|---|---|---|
| Revenue | 102.87M | 10.47M |
| Cost of Revenue | 3.53M | 1.20M |
| Gross Profit | 99.34M | 9.27M |
| Operating Expenses | 90.86M | 7.82M |
| Operating Income | 8.48M | 1.45M |
| EBITDA | 8.56M | 1.51M |
| Interest Expense | 65.75K | - |
| Pretax Income | 8.42M | 1.47M |
| Tax Provision | -7.10M | 707.68K |
| Net Income | 15.52M | 761.05K |
| Diluted EPS | - | 0.03 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|
| Revenue | 4.34M | 6.88M | 16.69M | 301.83M |
| Cost of Revenue | 1.47M | 881.75K | 1.26M | 13.75M |
| Gross Profit | 2.87M | 5.99M | 15.42M | 288.08M |
| Operating Expenses | 4.47M | 10.67M | 23.20M | 256.88M |
| Operating Income | -1.61M | -4.68M | -7.78M | 31.20M |
| EBITDA | -602.00K | -6.52M | -7.55M | 31.49M |
| Interest Expense | 525.88K | 468.15K | 700.33K | 587.22K |
| Pretax Income | -1.41M | -7.23M | -8.48M | 30.61M |
| Tax Provision | 0 | 0 | 0 | -1.27M |
| Net Income | -1.45M | -7.19M | -8.48M | 31.88M |
| Diluted EPS | -0.12 | -0.63 | -0.62 | 1.47 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|
| Total Assets | 2.67M | 3.47M | 14.56M | 140.38M |
| Current Assets | 938.60K | 1.49M | 12.60M | 133.76M |
| Cash & Equivalents | 340.33K | 772.14K | 239.41K | 22.83M |
| Inventory | 260.05K | 395.23K | 658.68K | 1.82M |
| Receivables | 300.14K | 37.21K | 11.37M | 104.98M |
| Total Liabilities | 8.47M | 7.42M | 15.90M | 99.50M |
| Current Liabilities | 6.54M | 6.33M | 15.62M | 99.17M |
| Long Term Debt | 1.80M | 1.03M | 265.63K | 150.00K |
| Total Debt | 4.83M | 5.09M | 4.72M | 4.39M |
| Total Equity | -5.96M | -4.08M | -1.34M | 40.88M |
| Shares Outstanding | - | 12.16M | 16.23M | 16.66M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|
| Operating Cash Flow | -109.44K | 303.57K | -3.50M | 24.48M |
| Investing Cash Flow | -7.85K | -469.48K | -210.33K | -1.68M |
| Financing Cash Flow | 357.42K | 597.71K | 3.18M | -206.78K |
| Capital Expenditure | -42.85K | -469.48K | -210.33K | -426.57K |
| Free Cash Flow | -152.29K | -165.91K | -3.71M | 24.05M |
| Net Change in Cash | 240.13K | 431.80K | -532.73K | 22.59M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|
| Gross Margin % | 66.0% | 87.2% | 92.4% | 95.4% |
| Operating Margin % | -37.0% | -68.1% | -46.6% | 10.3% |
| Net Margin % | -33.3% | -104.6% | -50.8% | 10.6% |
| ROE % | 24.3% | 176.5% | 631.0% | 78.0% |
| ROCE % | 41.5% | 163.6% | 733.5% | 75.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BSEM
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE5uZTBvSndIazY1VlRUUEQyYWVGOXl6YVhpdUQ4YzBSWjBfNzJCd0xoWUdtTDhxUVJ1RzMyMm5OSUlCVFhEU2V4OE9XdzN0TzV3?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
A New York fireside chat will be available online Sept. 11 from BioStem Technologies - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOaks3UDk0cEN6T2N6Mk9pMG52cFkzRUlhRnVHa1huLWNNck8xYW4zazhCMW82Wjl2eUhGczY1bmNZVEIyWnBPZGZlVmJjSmh0OFdKd0d2SG5mUlBMVEZaX0xIRmltTGR6TU9sLUxLZlJkRW91NDIxWENILWFObldaNmpFaVpkT2J4YXpxZ3…
Biostem Technologies (BSEM) Stock Forecast and Price Target 2026 - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE5HSGgzT21BU2VkYUs1V0M4Ui1xY3AtX1VxY2dfZkdjS0lDV0M5TVQta3RDRmtKY2xRQjZmaFRjZzYzZjhQcmc1R0VGS19nZmY5c2syVVlEN0NqTTZNMWNiaXV6cHZ0QQ?oc=5" target="_blank">Biostem Technologies (BSEM) S…
BioStem Technologies, Inc. (BSEM) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNU2hFVG95RHN0b1Q3VEM2RWNObGttVHBDdk13ekVZVnBCRExBUFlJWHBWNG9nZmpnQUNUTnB5Ul9lLWNfYnNDb0hEblA5Smd4NTlZTEtTSjdiVWc3bVpUdElsWEF0SjNhbm9NYU5WUkdxS2VsMHZTdVRhcHdRMERiMVdycVQtNDB4WHh6cj…
Two wound-covering products gain hospital access for the first time. BioStem made them orderable immediately. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPM2t0M3VKeTUzVmR0WFM1NS1UbmdnTk90N3B4eFR0aUwtNG1aZVlBTGxsUVVMM0M0WWFoOG0yRXp4dVFUUThUeExiNXVJRlZ0NUpmTk5BTEhHQm0xTVlfSFFqcHF1UkhqU0tyTTVzWENwT3NxMldTcm9KTG9uTFpBUlhLRVZHM3o5OHVSTU…
Biostem Technologies (BSEM) Stock Price, News & Analysis - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTFBEV0kwWDV1NklBVHJOdE8xZHdMVHBPTUNLck10cnF3ZmdUeFlUNkdpMTI3NUg1N1pqd0lxeklseVVHZWh4VDdwMWhVSWlPa1ltTXJsQ2w0cEt2QQ?oc=5" target="_blank">Biostem Technologies (BSEM) Stock Price, News…
BSEM — Frequently Asked Questions
What is the current share price of BioStem Technologies, Inc. (BSEM)?
As of 2026-09-07 16:24 PDT, BioStem Technologies, Inc. (BSEM) trades at $3.71 on NasdaqCM. Its 52-week range is $3.00 to $10.68.
What is the market capitalisation of BSEM?
BioStem Technologies, Inc. (BSEM) has a market capitalisation of $63.01M on NasdaqCM.
What is the P/E ratio of BSEM?
BSEM trades at a trailing price-to-earnings (P/E) ratio of 4.22. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.18.
What is the return on equity (ROE) of BSEM?
BSEM has a return on equity (ROE) of -48.64%. Its return on capital employed (ROCE) is 75.72%.
Is BSEM a good stock to buy?
This page provides a data-driven analysis of BioStem Technologies, Inc. (BSEM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.